Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 2Ventricular Dysfunction 1Radiation Pneumonitis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Hypertension 1Essential Hypertension 1Cardiotoxicity 1Barrett Esophagus 1

Interventions

Doxorubicin 11Razoxane 5Dexrazoxane 5Electrocardiography 4Echocardiography 4Cyclophosphamide 4Vincristine 3Trastuzumab 3Granulocyte Colony-Stimulating Factor 3Filgrastim 3Exercise 3Etoposide 3Carvedilol 3Radiotherapy 2Prednisone 2Methotrexate 2Magnetic Resonance Spectroscopy 2Bleomycin 2salicylhydroxamic acid 1oblimersen 1hydrocortisone hemisuccinate 1dapagliflozin 1Vascular Stiffness 1VAP-cyclo protocol 1Tablets 1Silymarin 1Reverse Transcriptase Polymerase Chain Reaction 1Resistance Training 1Pulse Wave Analysis 1Palliative Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cardiotoxicity × Enalapril × Clear all
NCT00003070 2014-08-05

Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer

Children's Oncology Group

Phase 3 Completed
13 enrolled

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡